Scientific Program

Thursday, October 17, 2019

 08:00 – 16:20 Ultrasound Workshop
Supported by Novartis
Meeting Room 1/2
08:00 Opening Remarks
Speaker: Jean-Pierre Pelletier, Canada
08:05 Ultrasound in Rheumatoid Arthritis (I)
Moderator: Chi-Ching Chang, Taiwan
B-mode and doppler synovitis: Definition, detection and scoring
Ultrasound of bone, abnormalities:
1. Definition, detection and pitfalls
2. Validation and scoring
Speaker: Hilde Berner Hammer, Norway
08:35 Ultrasound in Rheumatoid Arthritis (II)
Moderator: Ko-Jen Li, Taiwan
Evidence-based role of ultrasound in rheumatoid arthritis
Speaker: Kai-Len Tsai, Taiwan
09:05 Break
09:20 Ultrasound in spondyloarthritis
Moderator: Jing-Chi Lin, Taiwan
1. Grey scale and doppler findings in enthesitis
2. Early differential diagnosis
Speaker: Po-Hao Huang, Taiwan
09:50 Evidence-based role of ultrasound in osteoarthritis
Moderator: Kuo-Lung Lai, Taiwan
Speaker: Kai Jieh Yeo, Taiwan
10:20 Break
10:35 Ultrasound in crystal-induced arthritis
Moderator: Ko-Jen Li, Taiwan
Speaker: Cheng-Hsun Lu, Taiwan
11:05 Ultrasound in large vessel vasculitis
Moderator: Ying-Chou Chen, Taiwan
Speaker: Yi-Da Wu, Taiwan
11:35 – 13:05 Lunch Break
13:05 Hands-on sessions:
Moderator: Ying-Chou Chen, Taiwan
a. Rheumatoid Arthritis
Tutors: Hilde Berner Hammer, Norway
              Kai-Len Tsai, Taiwan

b. Spondyloarthritis
Tutors: Kai Jieh Yeo, Taiwan
              Po-Hao Huang, Taiwan

c. Crystal-induced arthritis/osteoarthritis
Tutors: Kuo-Lung Lai, Taiwan
              Cheng-Hsun Lu, Taiwan

d. Vasculitis
Tutors: Jing-Chi Lin, Taiwan
              Yi-Da Wu, Taiwan

16:10 Closing remarks
Moderator: Chi-Ching Chang, Taiwan
 16:30 – 17:00 Opening Session Hall A
Chairperson  Jean-Pierre Pelletier, Canada
16:30 – 17:00 General Welcome
Jean-Pierre Pelletier, Canada
Johanne Martel-Pelletier, Canada
Boulos Haraoui, Canada
 17:00 – 17:10 Break
 17:10 – 18:10 Industry Symposium: Re-assessing the ESCEO algorithm for knee OA in the long-term perspective
Supported by Mylan
Hall A
Chairpersons Wen-Chan Tsai, Taiwan
Chung-Hwan Chen, Taiwan
17:10 Evidence for the long-term pharmacological management of osteoarthritis
Lucio Rovati, Italy
17:30 Treating osteoarthritis symptoms with symptomatic slow acting drugs for osteoarthritis (SYSADOAs): Update on most recent guidelines
Jean-Pierre Pelletier, Canada
17:50 Q&A/Discussion  
 18:10 Networking Reception

Friday, October 18, 2019

07:45 – 08:45 Round Table:
Headache for rheumatologists:
Arthritis pain and central sensitization syndrome

Hall A
Chairperson Kevin Pile, Australia
07:45 Is central sensitization a myth or a reality?
Lars Arendt-Nielsen, Denmark
08:05 How to cure the headache
Ying Ying Katy Leung, Singapore
08:25 Round Table Discussion
08:45 – 09:45 Round Table:
Osteoporosis in rheumatic diseases: A neglected story in rheumatology

Hall A
Chairperson Jean-Pierre Pelletier, Canada
08:45 Guidelines for treatment: Useful or not?
Kenneth G. Saag, USA
09:05 The Asian experience
Tien-Tsai Cheng, Taiwan
09:25 Round Table Discussion
 09:45 – 10:05 Coffee Break and Poster Viewing
10:05 – 11:05 Debate:
Biosimilars or Janus Kinase inhibitors (JAKi) should be the first line treatment of rheumatoid arthritis

Hall A
Chairperson Kimme Hyrich, UK
10:05 Biosimilars
Tore K. Kvien, Norway
10:25 JAKi
Tsutomu Takeuchi, Japan
10:45 Discussion
11:05 – 12:05 APLAR Session:
Novel approaches for osteoarthritis outcome prediction
Hall A
Chairperson Hilde Berner Hammer, Norway
11:05 Metabolomic prediction of osteoarthritis progression and treatment outcome
Guangju Zhai, Canada
11:25 Artificial intelligence approaches for the prediction of osteoarthritis progressors
Johanne Martel-Pelletier, Canada
11:45 Discussion
 12:05 – 12:20 Lunch Break and Poster Viewing
 12:20 – 13:20 Industry Symposium:
Expansion of treatment options in RA
Supported by Celltrion
Hall A
Chairperson Wen-Chan Tsai, Taiwan
12:20 – 12:25 Welcome and Introduction
Wen-Chan Tsai, Taiwan
12:25 – 12:40 The truth of biosimilar against clinicians’ concern
Tore K. Kvien, Norway
12:40 – 12:55 Future of biosimilar infliximab and global status
Tore K. Kvien, Norway
12:55 – 13:10 Compelling clinical evidence from real world data
Aileen Agbanlog, Philippines
13:10 – 13:20 Panel Discussion
13:20 – 14:20 Round Table:
Which biologics are safe for tuberculosis and/or hepatitis C?

Hall A
Chairperson Tsutomu Takeuchi, Japan
13:20 How big is the risk conferred by different biologics?
Masayoshi Harigai, Japan
13:40 How to prevent and monitor therapy
Der Yuan Chen, Taiwan
14:00 Round Table Discussion
14:20 – 15:20 Debate:
Intraarticular injections of platelet rich plasma for osteoarthritis treatment:
What to tell the patient

Hall A
Chairperson Jean-Pierre Raynauld, Canada
14:20 PRO
Chih-Chien Wang, Taiwan
14:40 CON
Rohini Handa, India
15:00 Discussion
 15:20 – 15:40 Coffee Break and Poster Viewing
15:40 – 16:40 Round Table:
Systemic lupus erythematosus: Biologic or non-biologic treatment?

Hall A
Chairperson Sandra V. Navarra, Philippines
15:40 SLE: Paradigm management changes
Thomas Dörner, Germany
16:00 Low-dose IL-2 treatment of SLE
Zhan-Guo Li, China
16:20 Round Table Discussion
 16:40 – 17:40 Taiwan Rheumatology Association Symposium:
Biosimilars in rheumatology: Perspectives around the world
Hall A
Chairperson Wen-Chan Tsai, Taiwan  
16:40 The Asian/Taiwan perspective
Wen-Chan Tsai, Taiwan
17:00 The Canadian and US perspective
Boulos Haraoui, Canada
17:20 The European/Scandinavian perspective
Tore K. Kvien, Norway
 17:40 Poster Session and Refreshments

Saturday, October 19, 2019

08:00 – 09:00 Consensus:
Cardiovascular risks in inflammatory arthritis: Risk assessment and management in daily practice
Hall A
Chairperson Yeong-Wook Song, Korea
08:00 What is the risk and what are the underlying mechanisms?
Lai Shan Tam, Hong Kong
08:20 Practical screening and management
Boulos Haraoui, Canada
08:40 Discussion
09:00 – 09:35 Oral Abstract Presentations
Hall A
Chairpersons Johanne Martel-Pelletier, Canada
Boulos Haraoui, Canada
09:00 OA:
Optimizing subject selection in knee osteoarthritis trials by joint space width: Analysis from a phase 2b trial of lorecivivint (SM04690)
Sarah Kennedy, USA
09:11 OA:
Wnt pathway modulation via CLK2 and DYRK1A inhibition by lorecivivint, a potential disease-modifying treatment for knee osteoarthritis
Tambiah Jeyanesh, USA
09:22 IA:
Controversy over the association between vitamin D and rheumatoid arthritis: A meta-analysis
Guntur Darmawan, Indonesia
 09:35 – 10:00 Coffee Break and Poster Viewing
10:00 – 11:00 Round Table:
Lessons learned from the registries: Did it change practice?
Hall A
Chairperson Tore K. Kvien, Norway
10:00 Comparative efficacy/effectiveness
Kimme Hyrich, UK
10:20 What to say and what to do for patients with a previous cancer
Wen-Chan Tsai, Taiwan
10:40 Round Table Discussion
 11:00 – 12:00 Industry Symposium:
The many faces of Janus Kinase inhibitors in rheumatology
Supported by Pfizer
Hall A
Chairperson Wen-Chan Tsai, Taiwan  
11:00 Mechanisms of action and rational for the use of JAK inhibitors in RA and PsA
Tsutomu Takeuchi, Japan
11:20 How to best use the JAK inhibitors: Lessons learned from the clinical trials and real life use
Boulos Haraoui, Canada
11:40 Q&A/Discussion  
 12:00 – 13:00 Lunch Break and Poster Viewing
13:00 – 14:30 Round Table:
Large vessel vasculitis: What are the options for investigation, disease treatment and management?

Hall A
Chairperson Boulos Haraoui, Canada
13:00 Role of imaging in diagnosing large vessel vasculitis
Simon Carette, Canada
13:20 Usefulness of biomarkers and gene expression profiling in exploring vasculitis
Peter C. Grayson, USA
13:40 Biological and non-biological drugs for the treatment of vasculitis
Yeong-Wook Song, Korea
14:00 Round Table Discussion
 14:30 – 14:45 Coffee Break and Poster Viewing
14:45 – 15:45 Debate:
Gout and crystal arthropathies: Benign diseases with a potentially deadly outcome
Hall A
Chairperson Lee S. Simon, USA
14:45 Prognosis/outcome of gout
Hyon Kyoo Choi, USA
15:05 Prevention/treatment of gout
Lisa Stamp, New Zealand
15:25 Discussion
15:45 – 16:45 Round Table:
The future of rheumatology: Reality and challenges
Hall A
Chairpersons Johanne Martel-Pelletier, Canada
Jean-Pierre Pelletier, Canada
15:45 Trial design
Lee S. Simon, USA
15:55 Rheumatology in Asia: Reality and dream
Sandra V. Navarra, Philippines
16:05 What will happen when biologics and targeted synthetic DMARDs will become less expensive?
Tore K. Kvien, Norway
16:15 Round Table Discussion
16:45 – 16:50 Closing Remarks
Hall A
Johanne Martel-Pelletier, Canada